Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma

被引：12

作者：

Ricciardolo, Fabio L. M. ^{[1
]}

Blasi, Francesco ^{[2
]}

Centanni, Stefano ^{[3
]}

Rogliani, Paola ^{[4
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, IRCCS Fdn Ca Granda, Milan, Italy

[3] Univ Milan, Resp Unit, San Paolo Hosp, Dipartimento Sci Salute, Milan, Italy

[4] Univ Roma Tor Vergata, Dept Syst Med, Unit Resp Clin Pharmacol, Rome, Italy

来源：

PULMONARY PHARMACOLOGY & THERAPEUTICS | 2015年 / 33卷

关键词：

Asthma; Inhaled corticosteroid; Bronchodilator; Long-acting beta 2 agonist; EXHALED NITRIC-OXIDE; LONG-ACTING BRONCHODILATORS; AIRWAY INFLAMMATION; ALVEOLAR MACROPHAGES; COMBINATION THERAPY; BRONCHIAL HYPERRESPONSIVENESS; BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; LYMPHOCYTE-ACTIVATION; PRESCRIBED FENOTEROL;

D O I：

10.1016/j.pupt.2015.05.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Orally inhaled agents are a key therapeutic class for treatment of asthma. Inhaled corticosteroids (ICS) are the most effective anti-inflammatory treatment for asthma thus representing the first-line therapy and bronchodilators complement the effects of ICSs. A significant body of evidence indicates that addition of a beta 2-agonist to ICS therapy is more effective than increasing the dose of ICS monotherapy. In this paper, pharmacological features of available ICSs and bronchodilators will be reviewed with a focus on fluticasone propionate/formoterol fumarate combination which represents the one of the most powerful ICS acting together with the most rapid active LABA. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：1 / 10

页数：10

共 125 条

[21] The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics
Capraz, Firuz
Kunter, Erdogan
Cermik, Hakan
Ilvan, Ahmet
Pocan, Suheyl
[J]. LUNG, 2007, 185 (02) : 89 - 96
[22] Oxidants and asthma
Caramori, G
Papi, A
[J]. THORAX, 2004, 59 (02) : 170 - 173
[23] Novel long-acting bronchodilators for COPD and asthma
Cazzola, M.
Matera, M. G.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 155 (03) : 291 - 299
[24] Cazzola M., 2014, MULTIDISCIP RESP MED, V9
[25] Long-acting muscarinic receptor antagonists for the treatment of respiratory disease
Cazzola, Mario
Page, Clive
Matera, Maria Gabriella
[J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2013, 26 (03) : 307 - 317
[26] β2-Agonist Therapy in Lung Disease
Cazzola, Mario
Page, Clive P.
Rogliani, Paola
Matera, M. Gabriella
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (07) : 690 - 696
[27] Pharmacology and Therapeutics of Bronchodilators
Cazzola, Mario
Page, Clive P.
Calzetta, Luigino
Matera, M. Gabriella
[J]. PHARMACOLOGICAL REVIEWS, 2012, 64 (03) : 450 - 504
[28] β2-adrenoceptor agonists: current and future direction
Cazzola, Mario
Calzetta, Luigino
Matera, Maria Gabriella
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (01) : 4 - 17
[29] Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma
Centanni, S
Carlucci, P
Santus, P
Boveri, B
Tarricone, D
Fiorentini, C
Lombardi, F
Cazzola, M
[J]. RESPIRATION, 2000, 67 (01) : 60 - 64
[30] Agonist efficacy and receptor desensitization: from partial truths to a fuller picture
Charlton, Steven J.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (01) : 165 - 168

← 1 2 3 4 5 6 7 8 9 10 →